title: Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer.
abstract: OBJECTIVE
  Although there is growing evidence supporting the hypothesis that fibroblast growth factor receptor 2 (FGFR2) is one of the few candidate genes linked with breast cancer susceptibility, the precise role of FGFR2 protein expression in breast cancer is still unknown. Our study examines FGFR2 protein expression in breast cancer and determines its associations with clinicopathological features and survival.
  
  
  METHODS
  Specimens from 125 invasive ductal carcinoma grade 2 (IDC2) breast cancer patients were investigated by immunohistochemistry for FGFR2 protein expression. Associations between the expression of FGFR2 and various clinicopathological features as well as survival status were studied.
  
  
  RESULTS
  Cytoplasmic and nuclear FGFR2 were expressed in 64.8% and 56.8% of breast cancer patients, respectively. Cytoplasmic FGFR2 expression was significantly associated with tumor size and TNM stage. Furthermore, patients with high expression levels of cytoplasmic and nuclear FGFR2 showed much lower overall survival (OS) and disease-free survival (DFS) rates than those patients with low FGFR2 expression. Cytoplasmic FGFR2 expression and lymph node metastasis were independent prognostic factors for both DFS and OS by multivariate analysis.
  
  
  CONCLUSIONS
  High FGFR2 expression is correlated with poor OS and DFS in breast cancer patients. It could be a biomarker for poor prognosis.
authors: Department of Breast Surgery, The Third Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Shanshan
authors: S
authors: Sun
authors: Yongdong
authors: Y
authors: Jiang
authors: Guoqiang
authors: G
authors: Zhang
authors: Hongtao
authors: H
authors: Song
authors: Xianyu
authors: X
authors: Zhang
authors: Youxue
authors: Y
authors: Zhang
authors: Xiaoshuan
authors: X
authors: Liang
authors: Qian
authors: Q
authors: Sun
authors: Da
authors: D
authors: Pang
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D003593:Cytoplasm / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000378:metabolism*; D015996:Survival Rate
chemical_list: C496353:FGFR2 protein, human; D051497:Receptor, Fibroblast Growth Factor, Type 2